迪生創建(00113.HK):私有化計劃失去時效 21日復牌
格隆匯7月18日丨迪生創建(00113.HK)發佈公告,於2025年7月18日舉行的法院會議上,私有化計劃不獲親身或委派代表出席法院會議並於會上投票的計劃股東批準。
由於該計劃不獲計劃股東於法院會議上批準,(i)該建議已失去時效且不會實施;(ii)該計劃將不會具有約束力及生效;(iii)不會撤銷股份在聯交所的上市地位;及(iv)公司將不會由2025年7月30日起暫停辦理股份過戶登記手續以確定在該計劃享有的權利。
公司將會向聯交所申請要求自2025年7月21日上午九時正起恢復公司股份於聯交所買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.